To Demonstrate the Relative Bioavailability of Bupropion HCI 300 mg Extended-Release Tablets Under Fasting Conditions
NCT ID: NCT00861939
Last Updated: 2017-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2004-03-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions
NCT01046214
To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions
NCT00883155
Clinical Study of Generic and Brand Bupropion in Depression
NCT02209597
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers
NCT02698553
Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers
NCT03420469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Bupropion HCl 300mg Extended Release Tablet
Bupropion HCI 300 mg Extended-Release Tablets EON
2
WELLBUTRIN XL 300mg Tablets
WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupropion HCI 300 mg Extended-Release Tablets EON
WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Treatment for drug or alcohol dependence.
18 Years
58 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sandoz
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sandoz Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
So R Hong, M.D.
Role: PRINCIPAL_INVESTIGATOR
Novum Pharmaceutical Research Services
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B032032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.